Skip to main page content

Long-term outcomes in a large cohort of Birdshot chorioretinopathy

My Session Status

What:
Paper Presentation | Présentation d'article
When:
2:50 PM, Sunday 18 Jun 2023 (5 minutes)
Where:
Québec City Convention Centre - Room 308 B | Salle 308 B

 

Authors: Keith Perry1, Mélanie Hébert2, Ryan Hendrick1, Mohammed Al Kaabi3, Anna Polosa3 Marie-Josée Aubin3. 1Université de Montréal, 2Hôpital Saint-Sacrement, CHU de Québec - Université Laval, 3Centre universitaire d'ophtalmologie, Hôpital Maisonneuve-Rosemont.

Author Disclosures: K. Perry: None. M. Hébert: Funded grants or clinical trials; Name of for-profit or not-for-profit organization(s); Bayer, Fighting Blindness Canada, Vision Health Research Network. Funded grants or clinical trials; Description of relationship(s); Research funding, Research funding, Research funding. R. Hendrick: None. M. Al Kaabi: None. A. Polosa: None. M. Aubin: Funded grants or clinical trials; Name of for-profit or not-for-profit organization(s); Vision Health Research Network. Funded grants or clinical trials; Description of relationship(s); Research funding.



Abstract Body: 

Purpose: To investigate the long-term outcomes in Birdshot chorioretinopathy. 

Study Design: Retrospective cohort study 

Methods: Patients with BSCR diagnosed since 1986 and followed by the uveitis service of the Centre universitaire d’ophtalmologie - Hôpital Maisonneuve-Rosemont were considered for inclusion (n=77). In this retrospective cohort study, patient files were reviewed in a standardized manner and pre-established clinical endpoints were collected at specific intervals. Data compilation was done using RedCap. 

Results: Median [Q1, Q3] duration of follow-up for the 77 patients was of 100 months [53, 163]. Median [Q1, Q3] age of this cohort at diagnosis was 53 [46, 59] years. Most BSCR patients were treated with biologics (87%). Duration of topical corticosteroids for treatment was 14 [6, 62] weeks. Periocular injections were administered in 26% of eYes, while intraocular injections were used in 21%. Cystoid macular edema (CME) defined as central subfoveal thickness (CST) greater than 295 μm occurred in 50% of eYes, while loss of visual field greater than a mean deviation of -12 was seen in 14% of eyes. Vasculitis involving two quadrants or more was reported in 24% of eyes at follow-up. Furthermore, initial CST was 287 [250, 344] μm compared to 245 [223, 288] microns at final follow-up (p=0.009). Retinal nerve fiber layer (RNFL) thickness also decreased from 106 [90, 125] μm to 93 [84, 106] μm between the initial visit and final follow-up (p<0.001). 

Conclusions: In BSCR, a major contributor to loss of vision is CME which should be treated aggressively using periocular and intraocular corticosteroid injections in addition to systemic immunomodulation. With treatment and follow-up, progressive decreases in CST and RNFL thickness are also seen.

My Session Status

Send Feedback

Session detail
Allows attendees to send short textual feedback to the organizer for a session. This is only sent to the organizer and not the speakers.
To respect data privacy rules, this option only displays profiles of attendees who have chosen to share their profile information publicly.

Changes here will affect all session detail pages